In Vivo Antibody
In Vivo Antibody - Related Videos
04:13
A Technique to Assess the In Vivo Localization of Tumor-Specific Antibodies
0 Views •
2025
This video demonstrates a technique to study the in vivo localization of tumor-specific antibodies in a mouse tumor xenograft model. Upon subcutaneously injecting cancer cells into mice for tumor formation, fluorescently-labeled antibodies are injected that bind to tumor-specific receptors, enabling in vivo assessment of antibody localization via imaging.
02:44
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
0 Views •
2025
This video demonstrates a method for tracking bispecific antibody-induced T cell trafficking to tumors in a mouse model. Luciferase-transduced effector T cells are injected into a mouse with a subcutaneous tumor cell xenograft. Bispecific antibodies are then introduced, binding to T cells and the tumor cells. The localization of the T cells is tracked using bioluminescent imaging, with the magnitude of the signal indicating the extent of T cell infiltration into the tumor.
03:10
In Vivo Fluorescence Imaging to Localize Antibodies in a Mouse Tumor Xenograft Model
0 Views •
2025
The video demonstrates a fluorescence imaging method for in vivo antibody localization in a mouse tumor xenograft model. It involves the injection of tumor cells in a mouse to generate solid xenografts beneath the skin. Subsequent injection of fluorescent antibodies confirms specific localization through enhanced fluorescence signals within the tumor xenograft.
08:09
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
0 Views •
Cited by 24 •
2015
This protocol outlines the steps required to perform ex vivo validation of in vivo near-infrared fluorescence xenograft imaging experiments in mice using fluorophore labelled nanobodies and conventional antibodies.
06:15
An In Vivo Immunofluorescence Localization Method to Study Antibody Biodistribution
0 Views •
2025
This video demonstrates an in vivo immunofluorescence localization (IVIL) technique to study the biodistribution of tumor-targeting antibodies in a murine model of breast cancer. Upon the intravenous injection of a tumor-specific antibody in the mouse, the tumor is surgically isolated, and the localization of the antibody within the tumor tissue is confirmed via ex vivo immunostaining.
FAQs
Antibody concentration affects how much target can be engaged, while tissue distribution determines whether the immunoglobulin reaches relevant microbial or cellular targets. Stability influences how long that activity can persist in the organism. Considering these variables together helps explain differences in protection, pathogen clearance, and the risk of harmful immune responses.
Binding and effector recruitment contribute different parts of the in vivo response. The antigen-binding region provides target recognition, whereas the Fc region connects the bound antibody with mechanisms including neutralization, opsonization, complement activation, and antibody-dependent cellular cytotoxicity. Examining both features shows whether target attachment is translated into effective immune defense.
An antibody’s effect cannot be interpreted from antigen binding alone because its Fc region can recruit immune mechanisms and interact with immune cells. In vivo studies therefore examine these interactions alongside antibody distribution and stability. This integrated view helps distinguish activity that improves pathogen clearance from responses that may be harmful.
Evaluation begins by relating antibody presence in the organism to its concentration, tissue distribution, and stability. Researchers then consider target recognition and the resulting recruitment of neutralization, opsonization, complement activation, or antibody-dependent cellular cytotoxicity. Linking these features to protection, pathogen clearance, or harmful immune responses provides a structured interpretation of in vivo activity.
Passive immunization is relevant when protection depends on antibodies supplied to a living organism rather than only on responses generated within it. In vivo study can show whether administered immunoglobulins reach appropriate tissues, remain stable, recognize their targets, and recruit protective mechanisms. These observations support assessment of antibody-based protection and therapeutic development.
Therapeutic antibody development uses in vivo evidence to connect molecular recognition with effects in the organism. Investigators can assess whether an antibody’s concentration and tissue distribution support target engagement, and whether Fc-associated mechanisms contribute to pathogen clearance. The same evaluation can reveal activity patterns that need to be controlled to limit harmful immune responses.
Vaccine evaluation can use in vivo antibody activity to examine whether immune responses produce antibodies that recognize relevant antigens and engage protective mechanisms. Measuring concentration, tissue distribution, and stability adds context beyond binding alone. These observations help relate vaccine-associated antibody responses to protection and to the balance between effective defense and harmful immune activity.